Resistance data for your leishmaniosis drug trial.
We profile drug-resistance markers in Leishmania infantum before and after treatment, map resistance across territories, and measure the drug's effect on the gut microbiome.
What we offer drug developers
Resistance profiling in trials
Classify enrolled dogs by resistance markers at baseline, and track marker changes in relapses.
Resistance surveillance
How common resistance markers are across countries and regions, for market and label decisions.
Gut-microbiome safety
Longitudinal gut-microbiome data during treatment, the design we have already published.
The tools behind it
The same validated methods our licensed labs use, plus whole-genome sequencing when you need the full picture.
- Validated resistance test qPCR test validated on 95 dogs, with 100% specificity.
- Digital PCR assays Precise, absolute quantification of each marker, even at low parasite loads in blood: useful as a trial endpoint.
- Leishmania whole-genome sequencing Structural variants and copy-number changes across the genome, from our own cohort of 48 genomes.
